New research published in the journal JAMA Dermatology shows that nicotinamide, a type of vitamin B3 supplement, can significantly reduce the risk of skin cancer returning.
These findings, derived from data from the U.S. Veterans Affairs (VA), confirm a 2015 clinical trial that showed that taking the supplement reduced the risk of skin cancer among 386 patients.
In this study, researchers compared data from 12,287 patients receiving nicotinamide with 21,479 individuals who did not take the supplement.
The results showed that the risk of skin cancer was 14% lower in the consumer group.
This study addressed the challenge of recording the use of nicotinamide, which is freely available and often not mentioned in medical records, using the VA data warehouse.
Dermatologists have been recommending this supplement to patients with a history of skin cancer since 2015, and this new study provides stronger evidence for its effectiveness.
